Humanin appears in 3 registered trials, and none of them administers it
This is the cleanest example on the site of why a trial count on its own is worthless. Human…
Members only. Join to read the rest
For Research & Educational Discussion Only. Not Medical Advice
Mitochondrial-derived peptide
Also known as HN, MT-RNR2, Rattin
A peptide encoded in mitochondrial DNA, of real scientific interest as a signaling molecule, with no interventional human trial of it as a therapy.
What doses have been studied? What each trial gave, with the population it was given to.
This entry is preclinical
In shortA short peptide coded by your mitochondria rather than the DNA in the nucleus, which was genuinely surprising when described and remains the most interesting thing about it. It was found in surviving neurons from Alzheimer's brain tissue and studied since as a cell-protecting signal. Its use as a treatment runs well ahead of anything tested.
Humanin is a short peptide encoded within the mitochondrial genome rather than the nuclear one, which was a genuinely surprising finding when it was described and remains the most interesting thing about it. It was identified in surviving neurons from Alzheimer's brain tissue and has been studied since as a cytoprotective signaling molecule.
It belongs to a small family of mitochondrial-derived peptides that also includes MOTS-c, which this compendium covers separately. The research interest is real and largely mechanistic. Its use as an intervention runs well ahead of anything tested.
In shortIt is proposed to work through a receptor complex and, separately, by blocking proteins that trigger cell suicide. Levels in the blood fall with age, and that observation is the origin of most of the interest. It is also where the reasoning most often goes wrong: something declining with age does not establish that topping it back up reverses anything, and that has not been tested here.
Proposed to act through a receptor complex involving CNTFR, WSX-1 and gp130, and separately through interaction with pro-apoptotic proteins including BAX, suppressing apoptosis.
Circulating levels decline with age, and that observation is the origin of most of the interest in it. It is also where the reasoning most often goes wrong: something declining with age does not establish that restoring it reverses anything, and that inference has not been tested here.
In shortLab and animal work. Cell and animal studies report protective effects in models of Alzheimer's, restricted blood flow and metabolic stress, and human observation has linked blood levels to age and disease. The registry does hold trial entries, and they are worth reading carefully, because they measure it as a marker rather than give it to anyone. Nobody has ever been administered this.
Preclinical. Cell and animal work reports cytoprotective effects in models of Alzheimer's disease, ischemia, and metabolic stress, and observational human work has associated circulating levels with age and with disease states.
The trial registry does hold entries for it, and they are worth reading carefully, because they measure circulating humanin as a biomarker rather than give it to anyone. There is no interventional study of humanin as a therapy. "Registered trials exist" and "nobody has ever been administered this" are both true at once, and that combination is the whole content of this section.
In shortNo usable human safety data of any kind. No dose, route or duration in people has been characterized. A mechanism that blocks cell suicide deserves the same caution noted elsewhere here for growth-promoting compounds: stopping programmed cell death is not selectively good, and the cells that should die are the ones most likely to benefit.
No human safety data of any usable kind. There is no dose, route or duration in humans that has been characterized.
An anti-apoptotic mechanism deserves the same caution noted elsewhere in this compendium for pro-growth and pro-angiogenic compounds: suppressing programmed cell death is not selectively good, and cells that should die are the ones most likely to benefit.
In shortNot approved anywhere, for anything. Research-use-only material with no therapeutic authorization in any country.
Not approved anywhere, for anything. Research-use-only material with no therapeutic authorization in any jurisdiction.
2 studies indexed. Findings and limitations get equal weight, on purpose.
Members area
Everything above is free to read. What an account opens is the evidence underneath it: 2 studies with their limitations, and the regimen each trial actually reported.
Free to create. A membership is separate, and you can decide about that later.
Reading is free, an account is not the same as paying. 80 compound guides, every study with its limitations written underneath, and the regimens those trials actually used. A free account opens all of it. A membership is a separate decision, and it opens the forum. What membership costs.
The wider literature
27 indexed papers and 3 registered trials mentioning Humanin, straight from PubMed and ClinicalTrials.gov. None of those trials administers it; they measure it. These have not been read by us. Unlike the studies above, they carry no findings and no limitations written by anyone here, because writing either would mean claiming a reading nobody has done. They are a starting point for yours.
University of Gaziantep2026NCT07678073
interventionalnarecruitingn=68
Guangdong Provincial People's Hospital2022NCT06105229
observationalunknownn=60
University of Tartu2018NCT03431844
observationalcompletedn=106
Mun H, et al.Aging2026PMID 41747288
journal article
Coradduzza D, et al.Clinical and experimental medicine2025PMID 40768089
journal article
Maraux M, et al.Cell death & disease2025PMID 40877234
journal article
Huang J, et al.Molecular human reproduction2025PMID 40811024
journal articleresearch support, non-u.s. gov't
Thakur R, et al.Molecular neurobiology2025PMID 40715951
journal articlereview
Li Y, et al.Journal of advanced research2024PMID 38008175
journal articlereviewresearch support, non-u.s. gov't
Cheng J, et al.Cell reports. Medicine2024PMID 39053460
journal articleresearch support, non-u.s. gov't
Velentza L, et al.Journal of the Endocrine Society2024PMID 38328478
journal article
Kal S, et al.Peptides2024PMID 38160808
journal articlereviewresearch support, n.i.h., extramural
Delgado-Peraza F, et al.Alzheimer's research & therapy2023PMID 37730689
randomized controlled trialjournal articleresearch support, n.i.h., intramuralresearch support, non-u.s. gov't
Karachaliou CE, et al.Biology2023PMID 38132360
journal articlereview
Kim SK, et al.Nature communications2023PMID 37468558
journal articleresearch support, non-u.s. gov't
Burtscher J, et al.Aging cell2023PMID 36642986
journal articlereviewresearch support, non-u.s. gov't
Shan SK, et al.Frontiers in endocrinology2022PMID 36605935
editorialresearch support, non-u.s. gov't
Ikegawa N, et al.Biochimica et biophysica acta. General subjects2022PMID 35843407
journal articleresearch support, non-u.s. gov't
Katiyar R, et al.Theriogenology2022PMID 36183493
journal article
Miller B, et al.The Journal of clinical investigation2022PMID 35499074
journal articlereviewresearch support, n.i.h., extramural
Woodhead JST, et al.Biochimica et biophysica acta. General subjects2021PMID 34520826
journal articlereview
Wang X, et al.Mitochondrion2020PMID 32980480
journal articleresearch support, n.i.h., extramuralresearch support, non-u.s. gov't
Rochette LAnnales de cardiologie et d'angeiologie2020PMID 32800320
editorial
Tiihonen J, et al.Molecular psychiatry2020PMID 31455857
journal articleresearch support, non-u.s. gov't
Merry TL, et al.American journal of physiology. Endocrinology and metabolism2020PMID 32776825
journal articleresearch support, n.i.h., extramuralresearch support, non-u.s. gov'treview
Popov LDCell and tissue research2019PMID 31131430
journal articlereview
Merdzo I, et al.American journal of physiology. Heart and circulatory physiology2019PMID 31490734
journal articleresearch support, n.i.h., extramuralresearch support, non-u.s. gov't
Mendelsohn AR, et al.Rejuvenation research2018PMID 30058454
journal articlereview
Gottardo MF, et al.Journal of cell communication and signaling2017PMID 28378125
journal article
Caricasole A, et al.FASEB journal : official publication of the Federation of American Societies for Experimental Biology2002PMID 12154011
journal article
Humanin has its own forum, and sits in Longevity & Healthspan. Every post says what kind of claim it makes.
This is the cleanest example on the site of why a trial count on its own is worthless. Human…
Members only. Join to read the rest
Membership
The guide above is open to everyone, and the literature underneath it opens with a free account. That is the educational half of this site. Reading and joining the discussion around Humanin, and every other entry, is what membership pays for.
For Research & Educational Discussion Only. Not Medical Advice
This guide is educational reference material compiled from published literature. It is not medical advice, not a recommendation, and not a substitute for a clinician who knows your history. Nothing here should be used to make a decision about your own health without one.
Talk to a licensed healthcare professional.